Douglas Hinerfeld
About Douglas Hinerfeld
Douglas Hinerfeld is a Senior Director of Application Support at Alamar Biosciences, Inc. and Ultima Genomics, with extensive experience in the biotechnology field and a Ph.D. in Genetics and Molecular Biology from Emory University.
Work at Alamar Biosciences
Douglas Hinerfeld serves as the Senior Director of Application Support at Alamar Biosciences, Inc. since 2023. In this role, he oversees the application support team, ensuring that clients receive effective solutions and assistance with Alamar's products. His extensive experience in the biotechnology sector contributes to the development and enhancement of application support strategies.
Previous Experience at Ultima Genomics
Before joining Alamar Biosciences, Douglas Hinerfeld held the position of Senior Director of Application Support at Ultima Genomics since 2022. In this capacity, he focused on providing high-level application support, leveraging his expertise to guide customers through the complexities of genomic technologies.
Career at NanoString Technologies
Douglas Hinerfeld has a significant history with NanoString Technologies, Inc., where he held multiple roles. He served as Principal Product Application Scientist from 2016 to 2019, and later as Director of Product Applications from 2019 to 2021. Additionally, he was the Senior Director of Customer Experience from 2021 to 2022. His contributions included enhancing product applications and customer engagement strategies.
Educational Background
Douglas Hinerfeld earned a Ph.D. in Genetics and Molecular Biology from Emory University, completing his studies from 1996 to 2001. He also holds a Bachelor of Arts in Psychology from The University of Colorado, where he studied from 1989 to 1995. His educational background provides a strong foundation for his work in the biotechnology field.
Contributions to Scientific Community
Douglas Hinerfeld has actively participated in the scientific community, presenting on the NULISA platform for profiling fluid-based neurodegenerative protein biomarkers. He also contributed to discussions on biofluid-based biomarkers for Alzheimer’s Disease at the Annual Meeting in Lisbon, Portugal. These activities reflect his commitment to advancing knowledge in molecular biology and genomics.